Drug industry unlikely to achieve their sales forecast.

Published: 2006-11-01 06:59:00

Updated: 2006-11-01 06:59:00

Most of local pharmaceutical companies seem hardly to achieve their sales target this year mainly because of the KFDA's delayed approval for the applications of new products stemming from the bio equivalency scandals and the parliamentary inspection of the government administration.

Especially...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK